



STOP
COVID-19

pure air

Il sistema che sanifica e deodorizza l'aria e le superfici
The system that sanitizes and deodorizes the air and the surfaces

Tested against COVID-19
DUCT MODULI A CANALE



TECHNICAL REPORT

VIRUCIDAL ACTIVITY STUDY OF THE "BIOXAIR MODELLO BXMCC2" PRODUCT (UNI EN 16777:2019)

Technical Report N° D202105303

Customer: SKILL GROUP S.r.l. - Società Unipersonale
Via Lombardia, 2
37044 Cologna Veneta (VR) Italy

Testing Laboratory LabAnalysis S.r.l.
Via Europa 5,
27041 Casanova Lonati (PV) Italy

Sample Submitted: Bioxigen Air Sanitizer "BIOXAIR MODELLO BXMCC2"
(batch N° MCC2 2102 0297)

LabAnalysis code: FD-21-002023-008515

Report Editing by: Fabio De Leonardis RALTBCF1
IL RESPONSABILE D'AREA TBCF
Fabio De Leonardis, PhD

Verified by: Guido Premoli DTAM



1. SUMMARY

The virucidal activity of the product was assessed exposing a surface pre-treated with a viral test suspension to the test item, at the conditions defined by the customer and described below. After the prescribed incubation time, the viral suspension was inoculated in the appropriate cellular monolayer. At the end of the incubation period, cellular cultures were observed by microscopy for the detection of cytopathic effects (CPE) produced by viral multiplication.

The verification of the methodology was performed in compliance to the reference method.

All detailed results for each test performed are reported in the chapter 2.

1.1 PRODUCT IDENTIFICATION

This study was conducted on the test item Bioxigen Air Sanitizer "BIOXAIR MODELLO BXMCC2", a static unit with bipolar ionization technology. See Table 1 for sample identification:

Table 1: Sample identification

Test item	Active Ingredient	Storage conditions	Batch	Production date	Expiry date	LabAnalysis internal code
Bioxigen Air Sanitizer "BIOXAIR MODELLO BXMCC2"	negative oxygen ions	n.a.	MCC2 2102 0297	02/2021	n.d.	FD-21-002023-008515

1.2 ASSAY SYSTEM

In order to evaluate the virucidal effectiveness the product was tested against the virus model inoculated in sensitive host cell line. See Table 2 for the biological system used for the tests of the study:

Table 2: Biological Assay System

Virus type	Host Cell Line
Vaccinia virus, strain Elstree, ATCC VR-1549	Vero cells, ATCC CCL-81

1.3 EXPERIMENTAL CONDITION

The test item was analysed at the following conditions summarized in Table 3:

Table 3: Virucidal Activity Assay Condition

Contact Temperature	20 ± 1 °C
Contact Time	15 / 30 / 45 / 60 minutes
Interfering Substance	0.3 g/L BSA (Clean conditions)
Sample concentrations	Saturated air condition by negative oxygen ions

This Technical Report concerns only the analyzed sample as received. This Technical Report cannot be partially reproduced without the written approval by LabAnalysis S.r.l. director.

1.3.1 METHOD OF SUPPRESSION (FOR REFERENCE TEST)

To suppress the virucidal activity, the mixtures of interfering substance, Reference material and virus suspension recovered with ice-cold medium from inoculated surface, were kept in ice bath during the serial dilutions preparation.

1.4 PERIOD OF ANALYSIS

Tests started on: 19/04/2021

Tests completed on: 06/05/2021

2. RESULTS

All the raw data recorded for each test of this study are reported in validated data sheet used to perform the computation of the required parameters following the Spearman-Kärber method.

2.1 VALIDATION OF THE ASSAY FOR VIRUCIDAL ACTIVITY

The results obtained to verify assay validity are reported in the Table 4 below. Due to the type of product under examination, some of the test recommended in the EN 16777 are not applicable.

Table 4: Assay Validation Results - Vaccinia virus, strain Elstree

Assay Performed	Results (with 95% confidence interval)	Assay Validity
Sample cytotoxicity	CPE < 1 (<25% damage to cell monolayer) in all dilutions tested	Not Applied
Virus stock solution titration	Virus Titre (-log TCID ₅₀ /mL) = 7.13 ± 0.36	VALID
Cell susceptibility to virus	Not Applied	Not Applied
Suppression of virucidal activity	Not Applied	Not Applied
Reference test for virus inactivation	TCID ₅₀ reduction after 5 min: 1.13 ± 0.52	VALID

It has been not possible to perform the test according to the standard due to the type of product under examination, however the presence of a cytotoxic effect on the control cells has been verified and therefore the filtration step has been introduced, as required by the standard.

The assay validity criteria for all the performed controls were satisfied.

2.2 VIRUCIDAL ACTIVITY ASSAY

The results obtained for the reduction of virus infectivity expressed as logarithm values, at the different incubation time points and conditions applied in the test are reported table 5.

This Technical Report concerns only the analyzed sample as received. This Technical Report cannot be partially reproduced without the written approval by LabAnalysis S.r.l. director.

Table 5: Results - Vaccinia virus, strain Elstree

Product Code/Name	Experimental Conditions		Control / Sample Virus Titre (-log TCID50/mL) with 95% confidence interval after contact time	Reduction with 95% confidence interval
	Incubation Time point (min)	Interfering Substance		
FD-21-002023-008515 "BIOXAIR MODELLO BXMCC2"	15	0.3 g/L BSA (Clean)	7.13 ± 0.36 / 5.50 ± 0.00	1.63 ± 0.36
FD-21-002023-008515 "BIOXAIR MODELLO BXMCC2"	30	0.3 g/L BSA (Clean)	7.13 ± 0.36 / 4.88 ± 0.37	2.25 ± 0.52
FD-21-002023-008515 "BIOXAIR MODELLO BXMCC2"	45	0.3 g/L BSA (Clean)	7.25 ± 0.33 / 3.50 ± 0.00	3.75 ± 0.33
FD-21-002023-008515 "BIOXAIR MODELLO BXMCC2"	60	0.3 g/L BSA (Clean)	7.50 ± 0.00 / 3.13 ± 0.36	4.37 ± 0.36

2.3 INTERPRETATION OF RESULTS

In agreement to the UNI EN 16777:2019 the product shall demonstrate a titre reduction of 4 log or more compared to the virus control titration ("PASS"), not considering the 95% confidential interval. Therefore, the results obtained in the present study can be summarized in the following Table 6:

Table 6: Assay Outcome

Product Code/Name	Experimental Conditions		Reduction with 95% confidence interval	Assay Outcome
	Incubation Time point (min)	Virus model		
FD-21-002023-008515 "BIOXAIR MODELLO BXMCC2"	15	Vaccinia virus, strain Elstree	1.63 ± 0.36	NOT PASS
FD-21-002023-008515 "BIOXAIR MODELLO BXMCC2"	30	Vaccinia virus, strain Elstree	2.25 ± 0.52	NOT PASS
FD-21-002023-008515 "BIOXAIR MODELLO BXMCC2"	45	Vaccinia virus, strain Elstree	3.75 ± 0.33	NOT PASS
FD-21-002023-008515 "BIOXAIR MODELLO BXMCC2"	60	Vaccinia virus, strain Elstree	4.37 ± 0.36	PASS

3. CONCLUSION

This Technical Report concerns only the analyzed sample as received. This Technical Report cannot be partially reproduced without the written approval by LabAnalysis S.r.l. director.

On the basis of the obtained results, operating following the indications of the UNI EN 16777, the device Bioxigen Air Sanitizer "BIOXAIR MODELLO BXMCC2" tested in clean conditions, at 20 °C proves virucidal activity against Vaccinia virus, after exposure of 60 minutes.

Therefore, the product can be considered effective against all enveloped viruses (including the coronaviruses such as SARS-Cov-2), as defined in the Annex A of the standard EN 16777:2019.

This Technical Report concerns only the analyzed sample as received. This Technical Report cannot be partially reproduced without the written approval by LabAnalysis S.r.l. director.

Annex A
(informative)

**Examples of viruses sorted according to their presence in the human body
in case of virus infection**

These viruses may contaminate hands, instruments, other surfaces and textiles.

NOTE 1 This list is not exhaustive.

NOTE 2 Enveloped viruses are in bold

Blood

Enterovirus

Filoviridae

Flavivirus

Herpesviridae

Hepatitis A Virus (HAV)

Hepatitis B virus (HBV)

Respiratory tract

Adenovirus (Mast-)

Coronavirus

Enterovirus

Herpesviridae

Neuronal tissue, ear and nose, eye

Adenovirus (Mast-)

Enterovirus

Herpesviridae

Measles Virus

Gastro-intestinal

Adenovirus(Mast-)

Caliciviridae

Coronavirus

Astrovirus

Skin, breast and/or milk

Enterovirus

Herpesviridae

Human Immunodeficiency Virus (HIV)

Hepatitis C virus (HCV)

Hepatitis Delta virus (HDV)

Human Immunodeficiency Virus (HIV)

Human T-Cell Leukaemia Virus (HTLV)

Parvovirus B 19

Influenza Virus

Paramyxoviridae

Rhinovirus

Rubella Virus

Human Immunodeficiency Virus (HIV)

Polyomavirus

Rabies Virus

Rubella Virus

Enterovirus

Hepatitis A Virus (HAV)

Hepatitis E Virus (HEV)

Rotavirus

Human T-Cell Leukaemia Virus (HTLV)

Papillomavirus

Poxviridae

Spleen and lymph nodes (see also „Blood“)

Human T-Cell Leukaemia Virus (HTLV)

Human Immunodeficiency Virus (HIV)

Dental procedure

Adenovirus(Mast-)

Enterovirus

Herpesviridae

Hepatitis B virus (HBV)

Urogenital tract

Hepatitis B Virus (HBV)

Herpesviridae

Human Immunodeficiency Virus (HIV)

Reference:

Van Regenmortel MHV et al.,Eds.: Virus Taxonomy, Classification and Nomenclature of Viruses, seventh report of the international committee on taxonomy of viruses.

Academic Press, San Diego, 2000

Hepatitis C Virus (HCV)

Hepatitis Delta Virus (HDV)

Human Immunodeficiency Virus (HIV)

Human T-Cell Leukaemia Virus (HTLV)

Papillomavirus

Polyomavirus



Skill Group S.r.l.
Via Lombardia, 2 - Cologna Veneta (VR) 37044 - ITALY
Tel +39 (0)41 5931151 | Fax +39 (0)41 5931158
www.bioxigen.com | sales@bioxigen.com

Distributore Autorizzato / Dealer